The First New Drug Application for a Classic Psychedelic Is Complete: What Compass Pathways' FDA Filing Means for Canadian Practitioners

On November 9, 2026, Compass Pathways announced that it has completed its submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for COMP360 in treatment-resistant depression (TRD). It is the first complete application for a classic psychedelic ever placed before the FDA.

As a Leader in Psychedelic News, ATMA CENA has followed this program through its trial readouts and, most recently, the company's October description of its launch plans. Today's development is different in kind: the filing itself is done.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

What Compass announced

The company's release states that the NDA is supported by two Phase 3 trials and a Phase 2b study that each met its primary endpoint, involving more than 1,000 participants with TRD. Chief executive Kabir Nath called it the largest late-stage clinical program in psychedelic treatments and said the company is focused on delivering COMP360 to patients as quickly as possible, subject to FDA approval.

The submission was a rolling one; in its November 3 third-quarter results Compass said the final piece would be filed within two weeks. The program holds FDA Breakthrough Therapy designation and a Commissioner's National Priority Voucher, which, according to the company and to Psychiatric Times, carries a review target of roughly one to two months rather than the standard timeline. Compass says launch readiness is on track for an expected launch in the first half of 2027, subject to FDA approval.

Two caveats sit inside the release itself. This is a company announcement, not an FDA decision; no approval has been granted. And COMP360 contains a Schedule I controlled substance, so the U.S. Drug Enforcement Administration and individual states must reschedule it before it could be sold, on a timeline Compass does not control.

The evidence behind the filing

According to HCPLive and Psychiatric Times, the two Phase 3 trials are:

COMP005, a U.S. trial of 258 participants comparing a single 25 mg dose of COMP360 with placebo. At week six, the 25 mg group showed a 3.6-point greater reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) than placebo (95% CI -5.7 to -1.5; P < .001). About 25 percent of the 25 mg arm achieved at least a 25 percent MADRS reduction after that single dose.

COMP006, a 581-participant trial across North America and Europe comparing two fixed doses of 25 mg, 10 mg or 1 mg given three weeks apart. At week six, the 25 mg arm showed a 3.8-point greater MADRS reduction than the 1 mg comparator (95% CI -5.8 to -1.8; P < .001), and 39 percent achieved a clinically meaningful reduction. The company reports that the benefit was maintained on average through at least week 26. Participants' current episodes averaged more than three years.

On safety, HCPLive reports 26-week serious adverse event rates in COMP006 of 5.7 percent in the 25 mg arm and 6.3 percent in the 1 mg arm, with nausea, headache, anxiety and visual hallucination the most common events, mostly on dosing day. Suicidal ideation was reported in under 1 percent of participants across the studies. An independent data safety monitoring board found no new or unexpected safety signals.

These are the sponsor's findings, and the FDA's job is now to test them. Practitioners should note that the effect sizes are modest in absolute MADRS terms, that COMP006 used a low active dose rather than an inert placebo, and that durability and functional-unblinding questions remain live.

Why the clinical model matters as much as the molecule

Gus Alva, MD, an investigator on both Phase 3 trials, told Psychiatric Times that the responses seen required anchoring with psychotherapy and trained therapist supervision. That matches how the trials were run: preparation, a monitored dosing session of several hours, and follow-up, delivered by trained staff.

Compass expects COMP360 to fit within the more than 8,500 U.S. treatment centres already certified to deliver an approved intranasal nasal-spray treatment, with provider training part of its readiness work. If the FDA approves, that training, and any risk evaluation and mitigation strategy the agency requires, will set a de facto standard other jurisdictions will study closely.

What it means in Canada

Nothing changes in Canadian law or practice today. The compound remains controlled under the Controlled Drugs and Substances Act, access outside clinical trials remains narrow and tightly restricted under federal controls, and an FDA decision is not a Health Canada decision.

But the implications are real. A U.S. approval would give Canadian clinicians, hospitals and regulators a concrete reference point for how psychedelic-assisted treatment is staffed, monitored and documented at scale, and would sharpen the questions provincial colleges and employers already ask about scope of practice, supervision and training hours. It would also increase patient enquiries, so front-line nurses, psychologists, physicians and therapists will need to explain accurately what has and has not been approved, for whom, and on what evidence.

For context, Compass is not alone: Psychedelic Alpha reported on November 2, citing anonymous sources and with no confirmation from the organisation, that the nonprofit Usona Institute has also completed an NDA for a psychedelic in major depressive disorder. If both reports hold, the FDA could be weighing two psychedelic applications at once in the coming months.

Preparing for what comes next

The filing is a milestone, not an endpoint. In the months ahead, practitioners can expect FDA questions and, if approval comes, a detailed label and risk-management framework that will define the clinical model.

For Canadian practitioners who want to be ready, the most useful preparation is grounding in the evidence, the screening and safety practices used in these trials, and the therapeutic frame around dosing. ATMA CENA's Advanced Pathways, which include the Psychedelic Therapy Foundations course as part one, are built around exactly that. If you would like to talk through which pathway fits your practice, you can book a call with a program advisor or explore the training programs.

ATMA CENA, Leader in Psychedelic News.

Sources

1. Compass Pathways Completes COMP360 New Drug Application to U.S. FDA for Treatment-Resistant Depression. Compass Pathways plc, press release (Business Wire), 2026.
2. NDA Submission Complete: COMP360 for Treatment-Resistant Depression. Psychiatric Times, 2026.
3. COMP360 NDA Submitted to FDA for Treatment-Resistant Depression. HCPLive, 2026.
4. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights. Compass Pathways plc, press release (Business Wire), 2026.
5. Breaking: Compass Files TRD New Drug Application with FDA. Psychedelic Alpha, 2026.
6. Usona Files Depression NDA as Race With Compass Tightens. Psychedelic Alpha, 2026.